SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Biocon’s arm divests BFI Non-Core Business to Eris Lifesciences

10 Nov 2023 Evaluate

Biocon’s subsidiary -- Biocon Biologics has divested the businesses in relation to its non-core branded formulations in India, comprising, inter alia, of generic dermatology and nephrology small molecule formulations (BFI Non-Core Business) to Eris Lifesciences on a ‘slump sale’ basis. Consideration received from such sale/disposal is Rs 366 crore including working capital adjustments. 

Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.


Biocon Share Price

418.40 3.15 (0.76%)
30-Jun-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1862.70
Dr. Reddys Labs. 1356.85
Cipla 1465.15
Zydus Lifesciences 1112.20
Lupin 2420.15
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: